


## Respiratory Pathogens Data Sep 02-Dec 17 2017


Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Myco plasma	Chla mydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI %FLU	EIA %FLU
DEC 10	0	32	6	4	70	18	55	11	6	45	4	1	0	252	42	587	7.2	n/a	n/a	16.5
Dec 03	0	15	1	3	50	22	69	10	7	46	13	3	0	239	19	532	3.6	8.4	5.6	12.4
NOV 26	0	13	0	1	31	23	60	11	3	23	4	2	1	172	14	423	3.3	6.7	3.9	
NOV 19	0	9	0	0	33	26	55	9	5	18	10	3	0	168	9	362	2.5	7.2	2.7	
NOV 12	0	3	0	0	20	26	64	7	2	23	8	1	0	154	3	421	0.7	4.4	1.2	2.6
NOV 5	0	4	0	0	9	26	68	2	8	11	6	5	0	139	4	390	1.0	4.4	1.2	2.8
OCT 29	0	0	0	0	6	30	67	0	2	4	1	4	0	114	0	333	0.0	3.4	1.0	1.4
OCT 22	0	1	0	0	3	35	79	1	1	12	3	0	0	135	1	360	0.3	2.9	0.9	1.1
OCT 14	0	0	0	0	3	24	59	1	2	2	2	0	1	94	0	364	0.0	2.5	0.9	1.6
OCT 8	0	0	1	0	6	33	91	3	0	2	0	2	0	138	1	333	0.3	2.7	1.8	2.8
Oct 01	0	0	0	0	1	18	73	1	3	0	2	1	0	99	0	340	0.0	2.0	1.0	3.0
SEPT 24	0	0	0	0	1	24	79	0	3	3	3	0	0	113	0	286	0.0	1.6	1.2	1.7
SEPT 17	0	0	0	0	3	9	93	1	4	0	3	1	0	114	0	314	0.0	1.6	1.3	3.5
SEP 9	0	0	0	0	0	18	94	3	2	2	0	0	0	119	0	359	0.0	1.7	1.5	1.8
SEP 2	0	0	1	0	0	12	49	0	5	1	1	1	0	70	1	234	0.4	1.8	1.1	2.7

Flu PCR  
% Rate


# ACL RESP. PANEL - POSITIVITY RATE All targets 42.9%



### ACL Influenza PCR POS 7.2%




### ACL FLUAG EIA POS 16.5%



CDC Dec 09, 2017 Positivity rate 8.4% - Flu A – 89% (2009 H1N1 -5% , seasonal H3 -93%) Flu B – 11.0%


## Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2017-2018 Season



## A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists\*


Week Ending Dec 09, 2017 - Week 49




\*This map indicates geographic spread and does not measure the severity of influenza activity.

The most prevalent target as Dec 09 is; Enterovirus (positivity rate 9.7%)


### ACL RMEPNL - CSF POSITIVE TARGETS





The most prevalent targets as Dec 9 are; **Giardia** and **E. histolytica**



The most prevalent target as Dec 9 are; NORO GII and GI virus







## Neuraminidase Inhibitors Resistance in Samples Collected - Oct 1- Dec 09, 2017,

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	<b>58</b>	<b>0</b>	<b>50</b>	<b>0</b>	<b>58</b>	<b>0</b>
Influenza A (H3N2)	<b>314</b>	<b>0</b>	<b>314</b>	<b>0</b>	<b>236</b>	<b>0</b>
Influenza B	<b>61</b>	<b>0</b>	<b>61</b>	<b>0</b>	<b>61</b>	<b>0</b>

### UpdateDec - 2017 PAHO/CDC

Target	Source	Period	CDC	US % POS	ACL 2017	ACL % POS	WSLH # cases	IDPH # cases
Locally acquired	US (endemic)	Jan-Dec 2017	<b>2</b>	<b>0.00</b>				
<b>Zika virus US import</b>	<u>US (travelers)</u>	Jan-Dec 2017	<b>367</b>	<b>0.11</b>	<b>2</b>	<b>0.4</b>	<b>4</b>	<b>6</b>
<b>Zika virus US territory.</b>	<u>US (local)Puerto Rico</u>	Jan-Dec 2017	<b>595</b>	<b>0.16</b>				
<b>Dengue US import</b>	<u>US (travelers)</u>	Jan-Dec 2017	<b>190</b>	<b>0.06</b>	<b>4</b>	<b>0.8</b>	n/a	n/a
<b>Dengue US territory</b>	<u>US (local)Puerto Rico</u>	Jan-Dec 2017	<b>9</b>	<b>0.00</b>				
<b>Chikungunya US import</b>	<u>US (travelers)</u>	Jan-Dec 2017	<b>85</b>	<b>0.03</b>	<b>4</b>	<b>0.8</b>	n/a	n/a
<b>Chikungunya US territory</b>	<u>US (local)Puerto Rico</u>	Jan-Dec 2017	<b>32</b>	<b>0.01</b>				